HOTH News and Press, Hoth Therapeutics Inc. From 04/15/20

NEW YORK , April 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Dr. Mark Poznansky , Co-Creator of VaxCelerate, a self-assembling vaccine (SAV) platform, appeared as a guest on MSNBC's All In with Chris Hayes ...

April 9, 2020 Palm Beach, FL – April 9, 2020 – Recent industry reports on the projected growth of the global dermatologicals markets predict a continued surge in revenues. A report from Allied Market Research said that the global dermatologicals market is expected to...

NEW YORK , April 9, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatolog...

NEW YORK , April 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced its joint venture entity with Voltron Therapeutics, Inc., HaloVax, has entered into a Sponsored Research Agreement with the Vaccine and Immunot...

NEW YORK , March 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has entered into a non-binding letter of intent ("LOI") with Isoprene Pharmaceuticals, Inc. to acquire the full licensing rights of VNLG-152 ...

Astrotech (NASDAQ: ASTC ) +59%  as breathTest -1000 confirmed to detect lung disease metabolites at parts per billion. More news on: Astrotech Corporation, MFA Financial, Inc., Hoth Therapeutics, Inc., Stocks on the move, , Read more ...

Humanigen ( OTCQB:HGEN ) has submitted a protocol synopsis to the FDA related to its planned Phase 3 study of lenzilumab for the prevention and treatment of cytokine storm in COVID-19 patients. More news on: Humanigen, Inc., Hoth Therapeutics, Inc., Allogene Therapeutics, Inc., Healthcar...

NEW YORK , March 27, 2020 /PRNewswire/ --  HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., announced they have reached an agreement with Hoth Therapeutics, Inc (NASDAQ: HOTH) (previously released) to advance an application of ...

An Emerging Markets News Commentary ORLANDO, Fla., March 24, 2020 (GLOBE NEWSWIRE) -- Bright and early Monday morning, H oth Therapeutics, Inc. (NASDAQ: HOTH)  released news that the Company had entered into a joint venture agreement with its joint venture partner, Volt...

Hoth Therapeutics (NASDAQ: HOTH ) has priced its public offering of 1,449,275 common shares at $3.45 per share, for expected gross proceeds of ~$5M. More news on: AIkido Pharma Inc., Hoth Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...